pamvac
Vaccineexperimental
Clinical trial activity
1 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2016 (NCT02647489)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Plasmodium falciparumImmunity, active
Plasmodium falciparum immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- pamvac
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02647489 | Phase 1 | May 1, 2016 | European Malaria Vaccine Initiative, Expres2ion Biotechnologies APS, Government of France, University of Copenhagen, University of Tuebingen |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| European Malaria Vaccine Initiative | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Expres2ion Biotechnologies APS | For profit | 1 | 0 | 1 | 2016 |
| Government of France | Government | 1 | 0 | 1 | 2016 |
| University of Copenhagen | Academic/Hospital | 1 | 0 | 1 | 2016 |
| University of Tuebingen | Academic/Hospital | 1 | 1 | 1 | 2016 |
5 organizations
Page 1 / 1